Curiosity, reassurance and convenience: Understanding public motivations for using Generative AI in symptom assessment

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction Generative artificial intelligence (GenAI) tools such as large language models are Generative artificial intelligence (GenAI) tools such as large language models are increasingly used for health information and symptom appraisal. While diagnostic benchmarking studies are expanding, little population-level evidence explains why individuals use GenAI for symptom assessment or how motivations relate to trust, perceived accuracy and preferences for integration within health systems. Methods We analysed data from the 2025 RADIANT VOICES cross-sectional survey of UK adults (n=1449). Participants reported GenAI use, motivations for symptom-related use, trust across use cases and comparative accuracy expectations. Internal consistency supported aggregation of trust (α=0.90) and perceived accuracy (α=0.87) scales. To compare symptom-assessment users with non-users, we applied 1:1 nearest-neighbour propensity score matching (caliper 0.2) across sociodemographic and digital-literacy covariates, achieving standardised mean differences <0.10. Weighted regression models with Benjamini–Hochberg correction were used for outcome comparisons. Results Overall, 62.8% reported using GenAI; 49.7% of these had used it to assess symptoms. The most common motivations were curiosity (72.3%), reassurance following a diagnosis (60.7%) and convenience (32.1%). Trust was highest for low-risk informational uses (self-care advice 75.3%) and lowest for urgent-care guidance (38.0%). Participants generally rated GenAI as less accurate than general practitioners (55.8% perceived lower accuracy) but more accurate than traditional non-AI symptom checkers (35.8% perceived higher accuracy). After matching, symptom-assessment users demonstrated higher overall trust (mean difference 0.60, p<0.001), higher perceived accuracy (mean difference 0.30, p<0.001) and greater support for NHS integration (OR=4.06, 95% CI 2.85–5.79). Support for transparency was near-universal (97.0%). Conclusion Public use of GenAI for symptom assessment is widespread and primarily motivated by curiosity, reassurance and convenience. Trust is risk-dependent, favouring informational tasks over urgent decisions. Integration strategies should prioritise scope clarity, human oversight and transparency.

Article activity feed